Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen

Revenue up 13% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen
 
2Q Revenues: $4.5 billion (+13%)

2Q Earnings: $1.3 billion (+8%)

YTD Revenues: $8.5 billion (+11%)

YTD Earnings: $2.5 billion (+7%)

Comments: Neulasta and Neupogen sales were up 2% to $1.3 billion in the quarter. Enbrel sales rose 11% to $1.1 billion. Aranesp sales dropped 8% to $536 million, due to a decline in demand. Epogen sales decreased 3% to $525 million. Sensipar/Mimpara sales were up 17% to $232 million. Vectibix sales were up 11% to $90 million, and Nplate sales were up 15% to $86 million. Other revenues increased to $277 million in the quarter, versus $66 million in 2Q11, driven by changes to the company’s motesanib collaboration with Takeda.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters